Docetaxel for 15 patients with paclitaxel-resistant advanced non-small cell lung cancer

VernacularTitle:多西紫杉醇二线治疗紫杉醇耐药的晚期非小细胞肺癌15例
Author: Yifei ZHANG ; Yunhua XU ; Xiangyun YE ; Ziming LI ; Linping GU ; Shun LU
Publication Type:Journal Article
Keywords: Carcinoma,non-small-cell lung; Drug therapy doeetaxel
From: Cancer Research and Clinic 2009;21(7):458-460
CountryChina
Language:Chinese
Abstract: Objective To determine the efficacy and toxicity of docetaxel in patients with paclitaxel-resistant advanced non-small cell lung cancer (NSCLC). Methods The clinical data from 15 patients with NSCLC who were admitted in the Shanghai Chest Hospital from January 2005 to May 2008 were retrospectively analyzed. The effects and toxicities of the second-line treatment were assessed. The progression-free survival time(PFS) and overall survival time(OS) were analyzed. Results The disease control rate was 66.7 %, with a progression-free survival time of 6 months, and a overall survival time of 17.3 months. The 1-year survival rate was 63.3 %. The toxic effects were as expected. Conclusion The doeetaxel-based agent is active in patients with paelitaxel-resistant advanced NSCLC.